Growth in therapies targeting metabolic pathways, coupled with non-invasive imaging and biomarker development, is propelling the nonalcoholic fatty liver disease market to broader global adoption. https://www.datamintelligence.com/research-report/nonalcoholic-fatty-liver-disease-market